The expected outcome of a CLIN2 award is completion of a single interventional clinical trial. CIRM anticipates funding between 9-16 CLIN2 awards in fiscal year 2025-2026, contingent on the number of ...

South San Francisco, CA, April 24, 2025 — The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has approved awarding ...

Diabetes exacts a tremendous toll on patients, their families, and society in general. Autoimmune Type 1 diabetes, often called juvenile-onset diabetes, is caused by a person’s own immune system ...

Candidato terapéutico o dispositivo Células progenitoras autólogas derivadas de músculo (AMDC) aisladas de una biopsia de músculo esquelético Indicación Sujetos con disfagia (dificultades para tragar) ...

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse ...

间充质干细胞（MSC）是体细胞、多能基质细胞，具有有效的免疫调节和再生特性。尽管 MSC 具有模式识别受体并受到 Toll 样受体配体的调节，但 MSC 与微生物之间的相互作用尚不清楚。本研究的 ...

启动 – 发现阶段研究项目雪松 - 西奈医疗中心血脑屏障 (BBB) 芯片：开发和验证基于 iPS 的新型人类 BBB 微流体模型$241,992 临床试验阶段项目雪松 - 西奈医疗中心人类神经祖细胞分泌胶质细胞源性 ...

通常通过让患者在移植后继续服用抑制免疫系统正常反应的药物来预防移植器官的排斥。然而，免疫抑制（IS）对患者具有显着的长期健康影响。临床前研究表明，将供体的造血细胞注入受体 ...

The CIRM iPSC Repository is a collection of induced pluripotent stem cell (iPSC) lines produced from tissue samples obtained from thousands of individuals by researchers in California through funding ...